Literature DB >> 9593771

Increased expression of apolipoprotein E in transgenic rabbits results in reduced levels of very low density lipoproteins and an accumulation of low density lipoproteins in plasma.

J Fan1, Z S Ji, Y Huang, H de Silva, D Sanan, R W Mahley, T L Innerarity, J M Taylor.   

Abstract

Transgenic rabbits expressing human apo E3 were generated to investigate mechanisms by which apo E modulates plasma lipoprotein metabolism. Compared with nontransgenic littermates expressing approximately 3 mg/dl of endogenous rabbit apo E, male transgenic rabbits expressing approximately 13 mg/dl of human apo E had a 35% decrease in total plasma triglycerides that was due to a reduction in VLDL levels and an absence of large VLDL. With its greater content of apo E, transgenic VLDL had an increased binding affinity for the LDL receptor in vitro, and injected chylomicrons were cleared more rapidly by the liver in transgenic rabbits. In contrast to triglyceride changes, transgenic rabbits had a 70% increase in plasma cholesterol levels due to an accumulation of LDL and apo E-rich HDL. Transgenic and control LDL had the same binding affinity for the LDL receptor. Both transgenic and control rabbits had similar LDL receptor levels, but intravenously injected human LDL were cleared more slowly in transgenic rabbits than in controls. Changes in lipoprotein lipolysis did not contribute to the accumulation of LDL or the reduction in VLDL levels. These observations suggest that the increased content of apo E3 on triglyceride-rich remnant lipoproteins in transgenic rabbits confers a greater affinity for cell surface receptors, thereby increasing remnant clearance from plasma. The apo E-rich large remnants appear to compete more effectively than LDL for receptor-mediated binding and clearance, resulting in delayed clearance and the accumulation of LDL in plasma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9593771      PMCID: PMC508803          DOI: 10.1172/JCI1599

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  64 in total

1.  Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation.

Authors:  M F Linton; R Gish; S T Hubl; E Bütler; C Esquivel; W I Bry; J K Boyles; M R Wardell; S G Young
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

Review 2.  Properties of lipoproteins responsible for high affinity binding to cell surface receptors of fibroblasts and smooth muscle cells.

Authors:  R W Mahley; T L Innerarity
Journal:  Adv Exp Med Biol       Date:  1978       Impact factor: 2.622

3.  Effects of heparin on lipoprotein lipase from bovine milk.

Authors:  P H Iverius; U Lindahl; T Egelrud; T Olivecrona
Journal:  J Biol Chem       Date:  1972-10-25       Impact factor: 5.157

4.  Amino acid sequence of rabbit apolipoprotein E.

Authors:  B R Lee; J M Miller; C Y Yang; L Ramdas; M L Yang; J D Morrisett; M P Mims
Journal:  J Lipid Res       Date:  1991-01       Impact factor: 5.922

5.  Hepatic lipase hydrolysis of lipid monolayers. Regulation by apolipoproteins.

Authors:  T Thuren; R W Wilcox; P Sisson; M Waite
Journal:  J Biol Chem       Date:  1991-03-15       Impact factor: 5.157

6.  Chylomicron metabolism. Chylomicron uptake by bone marrow in different animal species.

Authors:  M M Hussain; R W Mahley; J K Boyles; P A Lindquist; W J Brecht; T L Innerarity
Journal:  J Biol Chem       Date:  1989-10-25       Impact factor: 5.157

7.  Clearance of chylomicron remnants by the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor.

Authors:  M M Hussain; F R Maxfield; J Más-Oliva; I Tabas; Z S Ji; T L Innerarity; R W Mahley
Journal:  J Biol Chem       Date:  1991-07-25       Impact factor: 5.157

8.  Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein.

Authors:  U Beisiegel; W Weber; G Bengtsson-Olivecrona
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

9.  Use of an anti-low density lipoprotein receptor antibody to quantify the role of the LDL receptor in the removal of chylomicron remnants in the mouse in vivo.

Authors:  S Y Choi; L G Fong; M J Kirven; A D Cooper
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

10.  Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins.

Authors:  R C Kowal; J Herz; J L Goldstein; V Esser; M S Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

View more
  19 in total

1.  Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizing.

Authors:  Robert W Mahley; Yadong Huang
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

Review 2.  Rabbit models for the study of human atherosclerosis: from pathophysiological mechanisms to translational medicine.

Authors:  Jianglin Fan; Shuji Kitajima; Teruo Watanabe; Jie Xu; Jifeng Zhang; Enqi Liu; Y Eugene Chen
Journal:  Pharmacol Ther       Date:  2014-09-30       Impact factor: 12.310

3.  Lipoprotein(a) promotes smooth muscle cell proliferation and dedifferentiation in atherosclerotic lesions of human apo(a) transgenic rabbits.

Authors:  Tomonaga Ichikawa; Hiroyuki Unoki; Huijun Sun; Hiroaki Shimoyamada; Santica Marcovina; Hisataka Shikama; Teruo Watanabe; Jianglin Fan
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

4.  A physiological function for apolipoprotein(a): a natural regulator of the inflammatory response.

Authors:  Jane Hoover-Plow; Erika Hart; Yanqing Gong; Aleksey Shchurin; Tracey Schneeman
Journal:  Exp Biol Med (Maywood)       Date:  2008-11-07

5.  Human C-reactive protein does not promote atherosclerosis in transgenic rabbits.

Authors:  Tomonari Koike; Shuji Kitajima; Ying Yu; Kazutoshi Nishijima; Jifeng Zhang; Yukio Ozaki; Masatoshi Morimoto; Teruo Watanabe; Sucharit Bhakdi; Yujiro Asada; Y Eugene Chen; Jianglin Fan
Journal:  Circulation       Date:  2009-11-09       Impact factor: 29.690

6.  Human apolipoprotein A-II protects against diet-induced atherosclerosis in transgenic rabbits.

Authors:  Yao Wang; Manabu Niimi; Kazutoshi Nishijima; Ahmed Bilal Waqar; Ying Yu; Tomonari Koike; Shuji Kitajima; Enqi Liu; Tomohiro Inoue; Masayuki Kohashi; Yuka Keyamura; Tomohiro Yoshikawa; Jifeng Zhang; Loretta Ma; Xiaohui Zha; Teruo Watanabe; Yujiro Asada; Y Eugene Chen; Jianglin Fan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-12-13       Impact factor: 8.311

7.  Lp(a)/apo(a) modulate MMP-9 activation and neutrophil cytokines in vivo in inflammation to regulate leukocyte recruitment.

Authors:  Menggui Huang; Yanqing Gong; Jessica Grondolsky; Jane Hoover-Plow
Journal:  Am J Pathol       Date:  2014-03-17       Impact factor: 4.307

Review 8.  Biologic therapies for dyslipidemia.

Authors:  Michael H Davidson
Journal:  Curr Atheroscler Rep       Date:  2004-01       Impact factor: 5.113

9.  Apolipoprotein CIII Deficiency Protects Against Atherosclerosis in Knockout Rabbits.

Authors:  Haizhao Yan; Manabu Niimi; Fumikazu Matsuhisa; Huanjin Zhou; Shuji Kitajima; Yajie Chen; Chuan Wang; Xiawen Yang; Jian Yao; Dongshan Yang; Jifeng Zhang; Masami Murakami; Katsuyuki Nakajima; Yao Wang; Enqi Liu; Jingyan Liang; Y Eugene Chen; Jianglin Fan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-08-06       Impact factor: 8.311

Review 10.  The transgenic rabbit as model for human diseases and as a source of biologically active recombinant proteins.

Authors:  Zs Bosze; L Hiripi; J W Carnwath; H Niemann
Journal:  Transgenic Res       Date:  2003-10       Impact factor: 2.788

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.